Collectively, these data from above suggest that FGF21D2D3 may ameliorate cardiac pathological changes to a greater extent than FGF21WT in T2D mice, likely via FGFR1–AMPKa signaling pathway-mediated inhibition of local oxidative stress in the heart. This evidence concerns the gene FGFR1 and type 2 diabetes mellitus.